Kornimate/medical-research-clean huggingface dataset:
abdominal binding in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease; Dyspnea

Summary: conventional approaches to relieve dyspnea (respiratory discomfort) in chronic obstructive pulmonary disease (copd) have focused on improving respiratory motor drive (e.g., hyperoxia) and/or dynamic respiratory mechanics (e.g., bronchodilators). although these approaches yield meaningful symptom improvements there remains many copd patients incapacitated by dyspnea. accumulating evidence suggests that abdominal binding (ab) is a potentially novel method of improving respiratory muscle function and, by extension, dyspnea and exercise tolerance in copd. thus, the purpose of this randomized, cross-over study is to test the hypothesis that ab improves exertional dyspnea and exercise tolerance in symptomatic patients with copd by improving dynamic respiratory muscle function. to this end, the investigators will examine the effects of ab on detailed assessments of baseline pulmonary function (spirometry, plethysmography), dyspnea (sensory intensity \& affective responses), neural respiratory drive (diaphragm emg), contractile respiratory muscle function (esophageal, gastric \& transdiaphragmatic pressures), ventilation, breathing pattern and cardiometabolic function during symptom-limited constant load cycle exercise (75% wmax) in 20 patients with gold stage ii/iii copd.


Eligibility criteria:
inclusion criteria: * male or female * aged ≥40 years * ambulatory * cigarette smoking history ≥15 pack years * no change in medication dosage or frequency of administration, with no exacerbations or hospitalization in the preceding 6 weeks. * post-bronchodilator forced expiratory volume in 1 second between 30-80% predicted * post-bronchodilator forced expiratory volume in 1 second/forced vital capacity ratio of \<70% exclusion criteria: * presence of active cardiopulmonary disease other than copd * use of domiciliary oxygen * exercise-induced arterial blood oxyhemoglobin desaturation to \<80% on room air. * body mass index \<18.5 or ≥35 kg/m2. * allergy to latex * allergy to lidocaine or its "caine" derivates.
arterial stiffness and decreased bone buffering capacity in hemodialysis patients

Conditions: Kidney Disease; Hypercalcemia

Summary: renal patients have an increased risk for cardiovascular complications. there is also increased vascular calcification and bone metabolism is similarly abnormal in patients with chronic kidney disease. in dialysis patients frequent episodes of hypercalcaemia occur. in a healthy bone structure those episodes of hypercalcemia are buffered by the bone. the absence of bone buffering capacity in dialysis patients can be a mechanism for vascular calcifications.

study hypothesis. patient with a higher ∆ calcium (calcium post - calcium pre) have a diminished bone buffering capacity indicative for adynamic bone disease compared with patients with smaller ∆ calcium. this may result in higher extraosseous calcification and higher pulse wave velocity ∆ pth/∆ calcium may reflect the sensitivity and density of the calcium receptors; this may reflect parathyroid "health"

Eligibility criteria:
inclusion criteria: * maintenance hemodialysis patients exclusion criteria: * dialysis \<3 months * aortobifemoral graft * calcium level predialysis \>10.5 mg/dl

Keywords: dialysis vascular calcification bone mineralism arterial stiffness bone metabolism chronic kidney disease
hiv patients cohort

Conditions: Patients Affected by the HIV

Summary: the purpose of this study is to improve our knowledge concerning hiv infection, treated or not, in the current conditions of care to optimize it.

since the arrival of highly active tritherapies, hiv infection became mainly an ambulatory chronic pathology centred on a long term care taking into account the complication of long-term treatment as well as the arisen of new problem bound to a prolonged survival and ageing. so the care is more and more in a prevention and screening approach with in particular the care of metabolic and cardiovascular complication due to antiretroviral treatment. as a reorganization of the coverage of the hiv infected people take place on the hotel dieu hospital it thus seems important to double this care optimization with a clinical research side. this will be done in constituting an hiv patient cohort including a blood sample collection to contribute to the vigilance of the complication to due the infection. our ultimate objective is to optimize the selection of the treatment. it is important to do it to be able to have, on many years duration, precise clinical information and biological sample allowing to realize later some assay and analyse the influence of some genetic markers.

Eligibility criteria:
inclusion criteria: * aged ≥18 years old, * patients with an hiv infection * patients having given their written informed consent.

Keywords: hiv, infection, cohort
a prospective real world study of rimegepant in the treatment of migraine

Conditions: Migraine

Summary: the goal of this observational study is to test the effectiveness and safety of rimegepant in the treatment of migraine patients in real world. the main questions it aims to answer are: * \[question 1\] the effectiveness and safety of rimegepant in the acute treatment of migraine * \[question 2\] the effectiveness and safety of rimegepant in the long-term treatment of migraine. 1. participants will be asked to take rimegepant when they need to treat or prevent a migraine attack. 2. participants will be asked to record the efficacy data at 0.5, 1, 2, 24, 48h post dose and report any ae to evaluate the effectiveness and safety of rimegepant in the acute treatment of migraine 3. participants will be asked to track monthly migraine days and the use of rimegepant, finish 2 pros during the follow-ups, report any ae to evaluate the effectiveness and safety of rimegepant in the long-term treatment of migraine.


Eligibility criteria:
inclusion criteria: * subjects diagnosed as migraines (with or without aura) consistent with a diagnosis according to the international classification of headache disorders, 3rd edition, beta version * rimegepant is prescribed by the physician for the treatment of patients with migraine. * patients signed written informed consent. * male and female subjects ≥ 18 years and older * patients is not participated in other concurrent interventional clinical studies. exclusion criteria: * the patients with severe visual, hearing, language, intelligence, memory, and consciousness disorders, are unable to cooperate with the completion of the questionnaire and follow-up. * pregnant patients * lactating female patients * patients who are highly dependent on medical care.
common and specific information from neuroimaging and smartphone

Conditions: Multiple Sclerosis

Summary: gait alteration is frequent in ms and limitation in walking ability is a major concern in ms patients. umanit and lmjl (nantes university) has developed a device call egait to assess walking ability in individuals (eg ms patients).

this device consists in a commercialized imu sensor (metamotionr sensor, mbientilab) worn at the right hip, a smartphone app and dedicated algorithm/mathematical model to extract raw sensor data and calculate individual gait pattern (igp). this igp consists of a curve, based on quaternion and representing the rotation recorded by the imu during an average gait cycle. pursue previous works conducted on (igp to assess) gait alteration in ms by adding (to igp) new information from mri.

Eligibility criteria:
inclusion criteria : * diagnosis of ms based on mcdonald criteria (including relapsing-remitting and progressive ms) * over 18 years old /age greater than 18 years * patients followed at nantes university hospital or rennes university hospital * last known edss before inclusion ranging from 0 to 6 inclusive/edss of 0 to 6 inclusive, prior inclusion * no relapse within 3 months * with a medullar mri planed as part as usual care * affiliated person or beneficiary of a social security scheme exclusion criteria : * bilateral aid needed to walk * women who are pregnant * patient having expressed their opposition * patient under guardianship or security measure

Keywords: wearable sensor gait mri
feasibility of the avecure microwave ablation technology for the bronchoscopic treatment of malignant central airway obstructions

Conditions: Airway Obstruction; Central Airway Obstruction

Summary: this research is being done to evaluate the feasibility of the avecure flexible microwave destruction of tissue (ablation) probe for the treatment of malignant central airway obstruction using a thin, tube-like instrument with a light and a lens for viewing and removing tissue (bronchoscopic). the name of the intervention being used in this research study is: avecure flexible microwave ablation probe (handheld, surgical device that delivers microwave energy via flexible probe tip)

this research study is a prospective, single-arm, cohort study to evaluate the feasibility of microwave ablation (mwa) probe for the bronchoscopic treatment of malignant lesions causing central airway obstructions (coa). the avecure prob will be placed in contact with the coa to treat with energy. the u.s. food and drug administration (fda) has approved this intervention for use throughout the body, but it has not been approved for the specific indication of central airway obstruction. research study procedures include screening for eligibility, hospitalization for bronchoscopy and mwa, blood tests, survey questionnaires, computerized tomography (ct) scan imaging, and pulmonary function tests. participation in this research study is expected to last about 6 months. it is expected that about 10 people will take part in this research study. medwaves, inc is funding this research study by providing the ablation probe and generator.

Eligibility criteria:
inclusion criteria: * patients age between 18 and 80 years of age and able to provide informed consent. * candidate for bronchoscopy under general anesthesia. * diagnosis of central airway obstruction (trachea, right main stem bronchus, left main stem bronchus), as evidenced by ct or ct/pet imaging confirmed or suspected to be due to malignant etiology, for which the bronchoscopist has deemed that endoscopic ablation/debridement is indicated (i.e. endobronchial tumors, mixed endobronchial/extrinsic compression lesions). exclusion criteria: * patients who are unable to understand the informed consent, including potential risks and benefits of the procedure. * patients in whom bronchoscopy under general anesthesia is contraindicated. * any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives * pacemaker, implantable cardioverter, or another electronic implantable device * patients with coagulopathy * patients in other therapeutic lung cancer studies * covid-19 positive patient at the time of the procedure. * patients who are pregnant * patients with purely extrinsic compression of the airway.

Keywords: endoluminal malignant central airway obstruction central airway obstruction
behavioral and neurofunctional correlates of intentional motor behaviors towards edible stimuli in normal-weight subjects

Conditions: Food Oriented Behavior

Summary: this study aims to investigate, through behavioural tests combined with advanced neurofunctional methods, the neural bases of intentional behaviours towards edible stimuli using explicit and implicit paradigms in normal-weight subjects. this knowledge will then be expanded with the study of associations between behavioral/neurofunctional measures and blood/hummon parameters.


Eligibility criteria:
inclusion criteria: * normal weight (body mass index - bmi - comprised between 18.6 and 24.99. * absence of usual contraindications to mri examination (e.g. pacemakers, fixed hearing implants, presence of metallic foreign bodies, intrauterine bodies, metallic splinters or fragments, metallic prostheses, screws, nails, fixed or mobile dental prostheses). * signature of informed consent and consent to cooperate in all study procedures. exclusion criteria: * previous diagnosis of significant neurological disorders (brain damage or dementia), major psychiatric disorders or eating disorders (binge-eating disorder, bulimia). * bmi less than 18.5 and greater than or equal to 25 kg/cm2. * serious medical conditions, including but not limited to: hypertension, significant heart disease, disorders or illnesses that may compromise patient safety. * pregnancy and claustrophobia.
virtual teaching kitchen

Conditions: Cardiac Health; Metabolic Syndrome

Summary: a novel way of delivering nutritional education is through experiential learning in a teaching kitchen setting. studies have shown that patients with metabolic syndrome who underwent a series of classes that featured nutrition recommendations and cooking classes had improved cardiac health. boston medical center (bmc) serves many underserved, low-income patients and has developed an innovative strategy to combat food insecurity and its consequences. this includes a preventative food pantry, a teaching kitchen, and a rooftop farm that provides fresh produce directly to the patients. the presence of this well-established three-pronged approach places our institution in an ideal position to develop a nutritional education intervention that supports experiential learning in this high-risk population. given the increasing focus on providing remote experiences to minimize contact and risk of infection with sars-cov-2, the investigators are proposing a study where patients can benefit from nutritional education virtually. patients with food insecurity and metabolic syndrome who utilize the food pantry will be invited to an educational program conducted on zoom. the program will be run by a registered dietician and chef who will deliver education virtually. data will be collected using surveys, phone interviews, chart review, and home monitoring to test both the feasibility of running such an intervention virtually and to explore whether attending this program improves cardiac health in patients.


Eligibility criteria:
inclusion criteria: * users of the food pantry * english speaking * must have one of following on their epic problem list (diabetes mellitus, obesity, hypertension, hyperlipidemia or obstructive sleep apnea) * must have documented measured blood pressure, weight, height in the 12 months prior to the intervention. exclusion criteria: * patients with advanced dementia or uncontrolled psychiatric disease * non-english speakers since education delivered in the pilot in english * uncontrolled medical illness including hypertension, recent acute coronary syndrome, active malignancy or other condition that would make the subject unable to complete the study procedures

Keywords: virtual nutritional education teaching kitchen food insecurity zoom media
a multi-center study to evaluate the safety and efficacy of pep005 (ingenol mebutate) gel, when used to treat actinic keratoses on non-head locations (trunk and extremities)

Conditions: Actinic Keratosis

Summary: the open label study is designed to assess the safety and efficacy of 0.05% pep005 gel when applied to an area of skin containing 4-8 ak lesions on non-head locations.


Eligibility criteria:
inclusion criteria: * patient is male or female and at least 18 years of age. * female patient must be of either: * non-childbearing potential, post-menopausal, or there is a confirmed clinical history of sterility (e.g., the patient is without a uterus) * childbearing potential, provided there are negative urine pregnancy test results prior to study treatment, to rule out pregnancy exclusion criteria * cosmetic or therapeutic procedures within two weeks and within 2 cm of the selected treatment area. * treatment with immunomodulators, interferon/ interferon inducers or systemic medications that suppress the immune system within 4 weeks. * treatment with 5-fu, imiquimod, diclofenac, or photodynamic therapy: within 8 weeks and 2 cm of the selected treatment area.

Keywords: peplin actinic keratosis pep005
an internet cognitive-behavioral intervention for youth with type 1 diabetes - participation and efficacy

Conditions: Type 1 Diabetes

Summary: adolescents are often reluctant to receive psychological help. the investigators developed a web-based cognitive behavioral self-help intervention for adolescents with type 1 diabetes. the investigators aimed to examine the participation rate and outcomes on glycemic control and quality of life.

adolescents are often reluctant to receive psychological help. the investigators developed a web-based cognitive behavioral self-help intervention for adolescents with type 1 diabetes. the investigators aimed to examine the participation rate and outcomes on glycemic control and quality of life. single center study was conducted to describe participation and efficacy of internet cognitive-behavioral intervention for youth with type 1 diabetes. adolescents with type 1 diabetes, aged 13-20 years, treated at a juvenile diabetes center, were offered to participate in the intervention. recruitment period lasted for 2 months, during january-february, 2011. hba1c measures of adolescents that agreed to participate, were obtained from medical records.the adolescents, that logged in, were asked to complete questionnaires before the intervention assessing their expectations of the program, quality of life and parental support. after completion of questionnaires, the adolescents were encouraged to complete 6 virtual sessions. satisfaction was assessed after each session. in the end of the program, participants were asked again to complete questionnaires. hba1c levels were obtained again for participants that logged in, and for participants that passively refused, 3 months or more after the recruitment.

Eligibility criteria:
inclusion criteria: * diagnosis with diabetes for at least 1 year * treated at juvenile diabetes center * fluent hebrew speakers exclusion criteria: * no previous diagnosis of a psychiatric condition (such as an eating disorder) * no opposition to the internet due to religious issues.

Keywords: adolescents cognitive behavioral internet intervention
bacteriophage effects on pseudomonas aeruginosa

Conditions: Cystic Fibrosis

Summary: pulmonary phage therapy to treat bacterial infections of the respiratory tract have been investigated in animals. the aim of the present study is to evaluate the efficacy of bacteriophages in infecting pseudomonas aeruginosa (pa) strains present in sputum samples. a cocktail of 10 bacteriophages will be applied on 60 sputum samples obtained from cystic fibrosis (cf) patients during 6 hours.we will determine the bacteria and bacteriophages strains in sputum samples collected. then the sensitivity of individual colony will be tested.


Eligibility criteria:
inclusion criteria: * informed consent * affiliated or benefit from a disease insurance regimen * men and women * aged from at least 6 years old * confirmed diagnosis of cystic fibrosis based on presence of 2 mutations of cftr gene and/or 2 positive tests of sweat chloride and/or 2 measures of pathologic difference of nasal potential associated to cystic fibrosis clinical signs. * patients able to produce sputum * pseudomonas aeruginosa chronic infected patients exclusion criteria: * simultaneous participation to another project on anti-infection, anti-inflammatory or modificating agents * subjet in exclusion period * law protected patient * realisation of sputum production is contra-indicated

Keywords: cystic fibrosis bacteriophages pseudomonas aeruginosa sputum
implementation and evaluation of "mindfulness-based cognitive therapy" in a health care region in flanders: a randomized clinical trial

Conditions: Recurrent Depression

Summary: research project regarding the possibility to implement and the efficacy of a non-drug, psychotherapeutic intervention (mbct), in preventing relapse/recurrence of depression.

this trial is based on the following publications: teasdale jd, segal zv, williams jmg, ridgeway va, soulsby jm, lau ma. prevention of relapse / recurrence in major depression by mindfulness-based cognitive therapy. journal of consulting and clinical psychology 2000; 68(4): 615-623. ma sh, teasdale jd. mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. journal of consulting and clinical psychology 2004; 72(1): 31-40.

Eligibility criteria:
inclusion criteria: * age: 18 years and above * place of residence in accordance with a well-defined region (pilot study) * given informed consent * diagnosis of recurrent depression (dsm-iv-tr) * at least 3 depressive episodes in the anamnesis (depression: either primary or secondary diagnosis) * last depressive episode at least 8 weeks ago (dsm-iv-tr) * absence of a present depressive episode * history of treatment by an antidepressant medication * hrsd-score \<14 at baseline assessment (hamilton rating scale for depression, hrsd-17) * absence of exclusion criteria exclusion criteria: * based on dsm-iv-tr: current diagnosis of any of the following psychiatric disorders: lifetime mood disorder, chronic depression, dysthymia, current substance abuse, obsessive-compulsive disorder, bipolar disorder, acute psychosis, cognitive disorder, organic mental disorder, pervasive developmental disorder, mental retardation, primary diagnosis of axis-ii-disorder, at risk for suicide * extended experience with zen- or vipassana meditation (or mindfulness) in the past or * more than 1 hour practice of zen- or vipassana meditation (or mindfulness) per week during the last 8 weeks * other meditation practices except for mbct during the training * more than 1 psychiatric consultation per 3-4 weeks during the training and follow-up * intensive psychotherapy during the training and follow-up * schizophrenia or schizoaffective disorder in the anamnesis * physical problems which make it difficult to participate in the programme

Keywords: recurrent depression mental health
antitumor t cell responses in patients with bladder cancer

Conditions: Bladder Cancer

Summary: the main objective of this study is to evaluate the induction of th1 anti-tert responses by treatments in patients with bladder tumor.


Eligibility criteria:
inclusion criteria: * patients undergoing transurethral resection of the bladder (turbt) for a tumor detected by cystoscopy with a histological diagnosis of a non-infiltrating or muscle-infiltrating tumor * for muscle-invasive tumors: localized tumors (t2-t3n0m0) or locally advanced (t4n0m0) * written informed consent exclusion criteria: * history of turbt for a bladder tumor whatever the stage * stages n1-3 or m1 on initial assessment * patients under immunotherapy, chemotherapy or other immunosuppressive drugs (prednisone or prednisolone ≤ 10 mg/day is allowed) * history of cancer in the last 3 years other than basal cell carcinoma or non-invasive cervical cancer * hiv, hepatitis c or b infection * patients with any medical or psychiatric condition or disease, * patients under guardianship, curatorship or under the protection of justice.